Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan 10;40(2):111-113.
doi: 10.1200/JCO.21.02549. Epub 2021 Dec 2.

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Sarah A Weiss  1 , Harriet Kluger  2
Affiliations
Editorial

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Sarah A Weiss et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Sarah A. WeissHonoraria: Baptist Health South FloridaConsulting or Advisory Role: Array BioPharmaResearch Funding: Bristol Myers Squibb (Inst), Apexigen (Inst)Travel, Accommodations, Expenses: Array BioPharma, Baptist Health South Florida Harriet KlugerConsulting or Advisory Role: Nektar, Celldex, Iovance Biotherapeutics, Merck¸ ElevateBio, Instil Bio, Clinigen Group, Shionogi, Bristol Myers Squibb, ChemoCentryx, Calithera Biosciences, SignateroResearch Funding: Merck (Inst), Bristol Myers Squibb (Inst), Apexigen (Inst)Travel, Accommodations, Expenses: ApexigenNo other potential conflicts of interest were reported.

Comment in

  • Reply to T. Olivier et al.
    Wolchok JD, Kluger H, Campigotto F, Larkin J, Hodi FS. Wolchok JD, et al. J Clin Oncol. 2022 May 10;40(14):1597-1598. doi: 10.1200/JCO.22.00209. Epub 2022 Mar 8. J Clin Oncol. 2022. PMID: 35258992 Free PMC article. No abstract available.

Comment on

  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Wolchok JD, et al. J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24. J Clin Oncol. 2022. PMID: 34818112 Free PMC article. Clinical Trial.

References

    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. : Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 373: 23–342015 - PMC - PubMed
    1. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. : Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 40: 127–1372022 - PMC - PubMed
    1. Olson DJ, Eroglu Z, Brockstein B, et al. : Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma. J Clin Oncol 39: 2647–26552021 - PMC - PubMed
    1. Zimmer L, Apuri S, Eroglu Z, et al. : Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer 75: 47–552017 - PubMed
    1. Schadendorf D, Wolchok JD, Hodi FS, et al. : Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials. J Clin Oncol 35: 3807–38142017 - PMC - PubMed